SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

AtriCure, Inc. – ‘10-K’ for 12/31/21 – ‘EX-23.1’

On:  Thursday, 2/17/22, at 3:27pm ET   ·   For:  12/31/21   ·   Accession #:  1323885-22-11   ·   File #:  0-51470

Previous ‘10-K’:  ‘10-K’ on 2/26/21 for 12/31/20   ·   Next:  ‘10-K’ on 2/22/23 for 12/31/22   ·   Latest:  ‘10-K’ on 2/16/24 for 12/31/23   ·   19 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 2/17/22  AtriCure, Inc.                    10-K       12/31/21  101:19M

Annual Report   —   Form 10-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   1.26M 
 2: EX-10.20    Material Contract                                   HTML     40K 
 3: EX-14       Code of Ethics                                      HTML    110K 
 4: EX-21       Subsidiaries List                                   HTML     27K 
 5: EX-23.1     Consent of Expert or Counsel                        HTML     27K 
 6: EX-31.1     Certification -- §302 - SOA'02                      HTML     32K 
 7: EX-31.2     Certification -- §302 - SOA'02                      HTML     32K 
 8: EX-32.1     Certification -- §906 - SOA'02                      HTML     29K 
 9: EX-32.2     Certification -- §906 - SOA'02                      HTML     29K 
15: R1          Cover                                               HTML     91K 
16: R2          Audit Information                                   HTML     32K 
17: R3          Consolidated Balance Sheets                         HTML    134K 
18: R4          Consolidated Balance Sheets (Parenthetical)         HTML     38K 
19: R5          Consolidated Statements of Operations and           HTML    127K 
                Comprehensive Income (Loss)                                      
20: R6          Consolidated Statements of Stockholders' Equity     HTML     85K 
21: R7          Consolidated Statements of Cash Flows               HTML    145K 
22: R8          Consolidated Statements of Cash Flows               HTML     29K 
                (Parenthetical)                                                  
23: R9          Description of Business and Summary of Significant  HTML     93K 
                Accounting Policies                                              
24: R10         Recent Accounting Pronouncements                    HTML     39K 
25: R11         Fair Value                                          HTML     85K 
26: R12         Investments                                         HTML     47K 
27: R13         Intangible Assets and Goodwill                      HTML     50K 
28: R14         Inventories                                         HTML     34K 
29: R15         Property and Equipment                              HTML     46K 
30: R16         Accrued Liabilities                                 HTML     37K 
31: R17         Indebtedness                                        HTML     39K 
32: R18         Leases                                              HTML    143K 
33: R19         Commitments and Contingencies                       HTML     35K 
34: R20         Revenue                                             HTML     36K 
35: R21         Income Taxes                                        HTML    107K 
36: R22         Concentrations                                      HTML     30K 
37: R23         Employee Benefit Plans                              HTML     30K 
38: R24         Equity Compensation Plans                           HTML    117K 
39: R25         Segment and Geographic Information                  HTML     63K 
40: R26         Schedule II - Valuation And Qualifying Accounts     HTML     52K 
41: R27         Description of Business and Summary of Significant  HTML    127K 
                Accounting Policies (Policies)                                   
42: R28         Description of Business and Summary of Significant  HTML     66K 
                Accounting Policies (Tables)                                     
43: R29         Fair Value (Tables)                                 HTML     78K 
44: R30         Investments (Tables)                                HTML     46K 
45: R31         Intangible Assets and Goodwill (Tables)             HTML     53K 
46: R32         Inventories (Tables)                                HTML     35K 
47: R33         Property and Equipment (Tables)                     HTML     45K 
48: R34         Accrued Liabilities (Tables)                        HTML     36K 
49: R35         Indebtedness (Tables)                               HTML     32K 
50: R36         Leases (Tables)                                     HTML     91K 
51: R37         Income Taxes (Tables)                               HTML    108K 
52: R38         Equity Compensation Plans (Tables)                  HTML    119K 
53: R39         Segment and Geographic Information (Tables)         HTML     60K 
54: R40         Description of Business and Summary of Significant  HTML     45K 
                Accounting Policies (Narrative) (Details)                        
55: R41         Description of Business and Summary of Significant  HTML     60K 
                Accounting Policies (Weighted Average Common                     
                Shares Outstanding) (Details)                                    
56: R42         Description of Business and Summary of Significant  HTML     47K 
                Accounting Policies (Accumulated Other                           
                Comprehensive Income (Loss)) (Details)                           
57: R43         Fair Value (Financial Assets And Liabilities        HTML     74K 
                Measured At Fair Value On A Recurring Basis)                     
                (Details)                                                        
58: R44         Fair Value (Narrative) (Details)                    HTML     67K 
59: R45         Fair Value (Level 3 Fair Value Measurements Using   HTML     37K 
                Significant Other Unobservable Inputs For                        
                Acquisition-Related Contingent Consideration)                    
                (Details)                                                        
60: R46         Investments (Narrative) (Details)                   HTML     29K 
61: R47         Investments (Summary Of Short-term Investments)     HTML     45K 
                (Details)                                                        
62: R48         Intangible Assets and Goodwill (Company's           HTML     42K 
                Intangible Assets) (Details)                                     
63: R49         Intangible Assets and Goodwill (Narrative)          HTML     46K 
                (Details)                                                        
64: R50         Intangible Assets and Goodwill (Future              HTML     43K 
                Amortization Expense Related To Intangible Assets                
                With Definite Lives) (Details)                                   
65: R51         Intangible Assets and Goodwill (Summary Of          HTML     32K 
                Company's Goodwill) (Details)                                    
66: R52         Inventories (Summary Of Inventories) (Details)      HTML     37K 
67: R53         Property and Equipment (Summary Of Property And     HTML     73K 
                Equipment) (Details)                                             
68: R54         Property and Equipment (Narrative) (Details)        HTML     36K 
69: R55         Accrued Liabilities (Accrued Liabilities)           HTML     43K 
                (Details)                                                        
70: R56         Indebtedness (Narrative) (Details)                  HTML     64K 
71: R57         Indebtedness (Future Maturities On Debt) (Details)  HTML     47K 
72: R58         Leases (Narrative) (Details)                        HTML     37K 
73: R59         Leases (Summary Of Weighted Average Remaining       HTML     38K 
                Lease Term And Discount Rate) (Details)                          
74: R60         Leases (Summary Of Components Of Lease Expense)     HTML     39K 
                (Details)                                                        
75: R61         Leases (Summary Of Supplemental Cash Flow           HTML     45K 
                Information Related To Leases) (Details)                         
76: R62         Leases (Summary Of Supplemental Balance Sheet       HTML     57K 
                Information Related To Leases) (Details)                         
77: R63         Leases (Schedule Of Maturities Of Lease             HTML     68K 
                Liabilities) (Details)                                           
78: R64         Commitments and Contingencies (Narrative)           HTML     46K 
                (Details)                                                        
79: R65         Revenue (Narrative) (Details)                       HTML     38K 
80: R66         Income Taxes (Summary Of Company's Provision For    HTML     58K 
                Income Taxes) (Details)                                          
81: R67         Income Taxes (Summary Of Detail Of Deferred Tax     HTML     59K 
                Assets And Liabilities) (Details)                                
82: R68         Income Taxes (Narrative) (Details)                  HTML     70K 
83: R69         Income Taxes (Summary Of Difference Between         HTML     68K 
                Effective Income Tax Rates And Federal Statutory                 
                Rate) (Details)                                                  
84: R70         Income Taxes (Summary Of Reconciliation of Change   HTML     38K 
                In Federal And State Unrecognized Tax Benefits)                  
                (Details)                                                        
85: R71         Concentrations (Details)                            HTML     40K 
86: R72         Employee Benefit Plans (Details)                    HTML     38K 
87: R73         Equity Compensation Plans (Narrative) (Details)     HTML    105K 
88: R74         Equity Compensation Plans (Activity Under Stock     HTML    114K 
                Based Compensation Plans) (Details)                              
89: R75         Equity Compensation Plans (Share-Based              HTML     44K 
                Compensation Expense Related To Employee                         
                Share-Based Compensation) (Details)                              
90: R76         Equity Compensation Plans (Assumptions Used For     HTML     46K 
                Determining Fair Value Of Options) (Details)                     
91: R77         Equity Compensation Plans (Assumptions Used For     HTML     45K 
                Determining Fair Value Of Stock) (Details)                       
92: R78         Equity Compensation Plans (Weighted Average         HTML     39K 
                Estimated Grant Date Fair Value Per Share Of Stock               
                Options, Restricted Stock Granted, And Performance               
                Awards) (Details)                                                
93: R79         Segment and Geographic Information (Narrative)      HTML     29K 
                (Details)                                                        
94: R80         Segment and Geographic Information (Revenue By      HTML     44K 
                Geographic Area) (Details)                                       
95: R81         Segment and Geographic Information (Revenue By      HTML     54K 
                Product Type) (Details)                                          
96: R82         Schedule II (Schedule Of Valuation And Qualifying   HTML     48K 
                Accounts) (Details)                                              
99: XML         IDEA XML File -- Filing Summary                      XML    188K 
97: XML         XBRL Instance -- atrc-20211231_htm                   XML   2.72M 
98: EXCEL       IDEA Workbook of Financial Reports                  XLSX    119K 
11: EX-101.CAL  XBRL Calculations -- atrc-20211231_cal               XML    261K 
12: EX-101.DEF  XBRL Definitions -- atrc-20211231_def                XML    634K 
13: EX-101.LAB  XBRL Labels -- atrc-20211231_lab                     XML   2.03M 
14: EX-101.PRE  XBRL Presentations -- atrc-20211231_pre              XML   1.19M 
10: EX-101.SCH  XBRL Schema -- atrc-20211231                         XSD    191K 
100: JSON        XBRL Instance as JSON Data -- MetaLinks              494±   726K  
101: ZIP         XBRL Zipped Folder -- 0001323885-22-000011-xbrl      Zip    508K  


‘EX-23.1’   —   Consent of Expert or Counsel


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 <!   C:   C: 
  Document  
 
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement No. 333-230001 on Form S-3 and Registration Statement Nos. 3333-240190, 333-232912, 333-226541, 333-226540, 333-219535, 333-216704, 333-199744, 333-194481, 333-187123, 333-180037, 333-173204, 333-173203, 333-165781, 333-165780, 333-157974, 333-157972, 333-152014, and 333-152013 on Form S-8 of our reports dated February 17, 2022, relating to the consolidated financial statements and financial statement schedule of AtriCure, Inc. and subsidiaries (the “Company”), and the effectiveness of the Company’s internal control over financial reporting, appearing in the Annual Report on Form 10-K of AtriCure, Inc. for the year ended December 31, 2021.
/s/ Deloitte & Touche LLP
Cincinnati, Ohio
February 17, 2022
 

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K’ Filing    Date    Other Filings
Filed on:2/17/22S-3ASR
For Period end:12/31/214,  SD
 List all Filings 


4 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/16/24  AtriCure, Inc.                    10-K       12/31/23  102:10M
 2/22/23  AtriCure, Inc.                    10-K       12/31/22   99:19M
 8/03/22  AtriCure, Inc.                    S-8         8/03/22    4:95K                                    Donnelley … Solutions/FA
 2/17/22  AtriCure, Inc.                    S-3ASR      2/17/22    6:847K                                   Donnelley … Solutions/FA


15 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

11/04/21  AtriCure, Inc.                    10-Q        9/30/21   72:6.9M
 2/26/21  AtriCure, Inc.                    10-K       12/31/20  111:23M
 5/22/20  AtriCure, Inc.                    8-K:5,9     5/20/20   11:444K
 4/29/20  AtriCure, Inc.                    8-K:1,2,7,9 4/29/20   13:4.3M
 2/24/20  AtriCure, Inc.                    10-K       12/31/19  109:23M
10/31/19  AtriCure, Inc.                    10-Q        9/30/19   78:12M
 8/12/19  AtriCure, Inc.                    8-K:1,2,3,7 8/11/19   14:7.9M                                   Donnelley … Solutions/FA
 7/31/19  AtriCure, Inc.                    10-Q        6/30/19   73:10M
 1/03/19  AtriCure, Inc.                    8-K:1,2,9  12/28/18    2:76K                                    Donnelley … Solutions/FA
 2/26/18  AtriCure, Inc.                    8-K:1,2,9   2/26/18    3:1.3M
 2/16/18  AtriCure, Inc.                    8-K:5,9     2/16/18    2:327K
 5/27/16  AtriCure, Inc.                    8-K:5,9     5/27/16    3:408K
 8/25/14  AtriCure, Inc.                    8-K:1,9     8/20/14    2:1.7M                                   Donnelley … Solutions/FA
 3/08/13  AtriCure, Inc.                    10-K       12/31/12   94:8.6M                                   Donnelley … Solutions/FA
11/01/12  AtriCure, Inc.                    8-K:1,2,5,911/01/12    4:263K                                   Donnelley … Solutions/FA
Top
Filing Submission 0001323885-22-000011   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., May 17, 5:56:01.2pm ET